Natural Capsules Limited has informed the Exchange regarding a press release dated May 28, 2026, titled "NATURAL CAPSULES LIMITED PRESS RELEASE".
NATCAPSUQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Natural Capsules reported Q4FY26 revenue of Rs 5.45 crore with EBITDA margin of 2.28% and a net loss of Rs 4.98 crore. For full year FY26, revenue stood at Rs 187.20 crore with EBITDA loss of Rs 1.56 crore and net loss of Rs 24.66 crore. The Q4 improvement was driven by dispatch of goods deferred due to prior quarter Puducherry plant shutdown, contributing approximately Rs 6 crore at higher profitability. Management guided FY27 to be a stable year for capsules with focus on capacity utilisation and operational efficiency. The new HPMC line for double-zero capsules is ready with revenue expected from H2 FY27 pending US client approval. API commercial sales commenced in Q4FY26, though management noted the current API business carries a lower margin profile awaiting regulatory clearances for higher-margin customers and geographies. Subsidiary Natural Biogenex signed fermentation CDMO agreements with Fermbox Bio for the Tumkur facility.
The company remains in loss-making territory for FY26 with weak EBITDA margins, though Q4 showed operational recovery. The guidance for FY27 stability and new HPMC line contribution provides some visibility, but the lower-margin API business and pending approvals create uncertainty around profitability improvement timeline.